Navigation Links
Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
Date:1/27/2011

ng plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does no
'/>"/>
SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
2. Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium
3. Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
4. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
5. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
6. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
7. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
8. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
9. European Hospital Anticoagulant Market Dominated by Sanofi-Aventiss Clexane
10. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
11. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... how to optimize a product,s web presence to ... critical. Brand websites, in particular, must meet the ... in regulations and culture. According ... LLC, more than half of the participating companies ...
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... results on Thursday, January 22, 2015, after the New York ... will be issued after 1:00 p.m. US Pacific Time and ... and future outlook. The earnings call is scheduled ... live webcast of the call can be accessed on ResMed,s ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2
... Continued Safety, Consistently Positive Clinical ... Results ... today from,Abbott,s SPIRIT III U.S. pivotal clinical trial demonstrated continued,positive, ... Stent System at one year, including continued,clinical superiority in major ...
... WASHINGTON, Oct. 22 The preliminary results ... OrbusNeich,s pro-healing stent, the,Genous Bio-engineered R stent, ... risk of restenosis patients show comparable efficacy ... de Winter, M.D., Ph.D.,principal investigator and director ...
Cached Medicine Technology:Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis 2
(Date:12/22/2014)... Petersburg, FL (PRWEB) December 22, 2014 Christmas ... Sublime Beauty® has a fast and easy solution that will ... gift cards can be purchased from from $25 up to ... "We offer 100% customer satisfaction and a wide array of ... have no fees and no expiration dates. , Gift ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... 22, 2014 Recently, BambooFlooringChina.com, a famous ... woven bamboo flooring collection , and launched a bamboo ... promotion is valid until Jan. 30, 2015. , According ... is the hardest bamboo flooring available today; it has ... of traditional teak hardwoods. Strand woven bamboo is made ...
(Date:12/21/2014)... Gables, FL (PRWEB) December 21, 2014 When ... head lice, who do they call? The new answer is ... Blvd, Coral Gables FL 33134, their newest treatment center will ... this pest quickly, conveniently and without the use of harmful ... Opening is scheduled for January 1, 2015. Like the company’s ...
(Date:12/21/2014)... 2014 Recently, one of the best ... Prom Shop has introduced its new collection of ... big discounts on all its prom dresses & other ... insists on providing top quality dress products and great ... considered as one of the best prom dresses online ...
Breaking Medicine News(10 mins):Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2
... (AMS), which affects about half of those ascending to heights ... pulmonary or cerebral edema. ,The interest of the general ... past 25 years. This change is partly due to media ... In spite of these apparent changes, it is unknown whether ...
... deadly bird flu since it is still rampant in the region, ... ,"I think countries in this part of the world have ... it, the virus is still circulating," said Shigeru Omi, WHO's regional ... We remain concerned. We must avoid human transmission," he told reporters ...
... patients who have already gone blind in one eye ... and Therapeutics Bulletin (DTB). ,But that is ... (NICE), the body responsible for guiding the NHS on ... (Lucentis) and pegaptanib (Macugen) are licensed in the UK ...
... Biotechnology Co., Ltd. announced that a team led by ... completed a study to assess clinical efficacy, safety, ... for patients with peripheral vascular disease of the lower ... research and treatments for ataxia, cerebral palsy, spinal cord ...
... Those involved in biological weapons programs should be logically liable ... it seems to have happened in US and the Centers ... research laboratory at Texas A&M University to stop all work ... investigating reports of lab workers infected with the category B ...
... personnel involved in the Iraqi invasion of 2003 have ... published ahead of print in Occupational and Environmental Medicine. ... combat to pierce armoured vehicles, and spontaneously combusts on ... breathed in or eaten/drunk in contaminated food/water. ...
Cached Medicine News:Health News:Acute Mountain Sickness may Lead to Pulmonary or Cerebral Edema 2Health News:Bird Flu in Asia Still High Risk Says WHO Official 2Health News:Draft National Policy on Sight-saving Drugs unacceptable 2Health News:Adult Stem Cells Show Promise for Peripheral Vascular Disease 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 3Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 4
... Designed for Western, Northern, or ... three gels with dimensions as large ... and internal cooling base for temperature ... attached power leads. Additional ...
... a component of Bio-Rad's modular mini electrophoresis ... high-quality blotting of mini gels. Its modular ... cm gels in just 1 hour. Cooling ... which absorbs heat generated during transfers. The ...
... Includes: 2 gel holder cassettes, ... cables, fiber pads, blot absorbent ... The Trans-Blot transfer cell, used ... supply, performs efficient, high-intensity electrophoretic ...
... Flexibility for a ... Transfers. Native Enzyme, ... Transfers. Faster, Higher-Efficiency ... High Field-Intensity Transfers ...
Medicine Products: